Lunesta Letter - Haymarket Media Group
Lunesta Letter - Haymarket Media Group
Lunesta Letter - Haymarket Media Group
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Cymbalta ® PRESCRIBING ALERT<br />
Delayed-Release Capsules<br />
(duloxetine HCI)<br />
Company: Eli Lilly and Company <br />
Pharmacologic class: Serotonin and<br />
norepinephrine reuptake inhibitor<br />
Indications: Management of fibromyalgia.<br />
Management of diabetic peripheral<br />
neuropathic pain (DPNP).Acute and<br />
maintenance treatment of major depressive<br />
disorder (MDD).Acute treatment of<br />
generalized anxiety disorder (GAD).<br />
Dosing: Fibromyalgia: 30-60 mg.*<br />
DPNP: 60 mg/day (once daily).<br />
MDD Acute: 40 mg/day (20 mg twice daily)<br />
to 60 mg/day (once daily or as 30 mg twice<br />
daily).<br />
MDD Maintenance: 60 mg/day.<br />
GAD Acute: 60 mg/day (once daily).<br />
Now approved for the<br />
management of fibromyalgia<br />
How supplied: Caps (20 mg,30 mg,<br />
60 mg)—100<br />
*Treatment should begin at 30 mg once daily for<br />
1 week, to allow patients to adjust to the medication<br />
before increasing to 60 mg once daily.<br />
In fibromyalgia, Cymbalta demonstrated significant and potent<br />
pain relief<br />
Cymbalta has demonstrated efficacy for patients with fibromyalgia<br />
CYMBALTA 60 MG/DAY IN FIBROMYALGIA CLINICAL TRIALS:<br />
1a †<br />
BPI 24-HOUR AVERAGE PAIN AT ENDPOINT<br />
Improvement<br />
% Change in Mean BPI 24-hour Average Pain<br />
Score Baseline to Endpoint<br />
100<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
*<br />
Cymbalta 60 mg/day (N=260)<br />
Placebo (N=257)<br />
2 pooled studies (LOCF)<br />
* P